Regeneus Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGS.AX research report →
Price Chart
About the company
Regeneus Ltd is an Australian clinical-stage company focused on regenerative medicine, creating cell-based treatments for various human health conditions. Its primary areas of research include osteoarthritis, a range of other musculoskeletal ailments, neuropathic pain, and dermatological disorders. The firm's leading platform technology, Progenza, offers a multi-synergistic therapy for addressing both osteoarthritis and neuropathic pain.
- CEO
- Karolis Rosickas
- IPO
- 2013
- HQ
- Paddington, NSW, AU
Get TickerSpark's AI analysis on RGS.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.68M
- P/E
- -2.18
- PEG
- -0.02
- P/S
- 0.00
- P/B
- -2.03
- EV/EBITDA
- -2.30
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 455.81%
- ROIC
- 96.69%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-6,419+74.3%
- Op Income
- $-2,249,110
- Net Income
- $-1,686,883+61.5%
- EPS
- $-0.01+61.5%
- OCF Growth
- +84.8%
- FCF Growth
- +84.9%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -0.24
- RSI (14)
- 49
- Avg Volume
- 616.96K
No earnings-call transcripts are available for RGS.AX yet.
- Free Float
- 52.7%
- Shares Outstanding
- 306.44M
- Float Shares
- 161.45M
Our RGS.AX coverage
Recent articles, reports, and earnings notes.
No research on RGS.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RGS.AX report →